POC Rapid Diagnostics Platform Leverages Graphene-Based Biosensors for Real-Time Disease Detection

A revolutionary graphene-based technology enables testing for a broad range of indications using a variety of sample types in less than five minutes at POC, placing high-performance diagnostics directly in the hands of medical professionals.

GrapheneDx (Boston MA, USA), an in vitro diagnostics company, is focusing on improving diagnostic capability at the point of care by industrializing graphene-based biosensors for medical devices used to diagnose a variety of diseases. Known for its superior electrical properties, graphene - a single-atom, thick layer of carbon - enables the highly accurate detection of diverse biomolecules. The medical devices developed by GrapheneDx are designed to match lab-quality accuracy, yield results in less than five minutes, and be easy enough to be used in professional healthcare settings.

Image: Graphene-based biosensors for medical devices can be used to diagnose a variety of diseases at POC (Photo courtesy of Freepik)

GrapheneDx has developed the GFET platform which demonstrates remarkable versatility in diagnosing various conditions such as sexually transmitted infections, respiratory and cardiac diseases, concussion, and more, using different sample types like stool, urine, swabs, blood, etc., with minimal or no sample preparation. Moreover, the platform has the capability to concurrently multiplex multiple analytes using a single patient sample. The first tests introduced by GrapheneDx will focus on the diagnosis of sexually transmitted infections, specifically Chlamydia and Gonorrhea, utilizing a noninvasive, easy-to-collect urine sample.

Related Links:
GrapheneDx